We are monitoring the impact of COVID-19 on Europe Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1114
Share on
Share on

Europe Antibodies Market Research Report – Segmented By Product Type, Indication, End User, Application & By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, Forecast, Growth (2020 to 2025)

Pulished: February, 2020
ID: 1114
Pages: 145

Europe Antibodies Market Size (2020 to 2025)

The size of the Antibodies Market in Europe is worth USD 31.78 Billion in 2020 and estimated to reach USD 54.55 Billion by the end of 2025 with a growing potential of 11.41 % during the forecast period.

An efficient resource to therapy of complex disorders with minor side-effects has enhanced the growth of antibodies based therapeutics against chemical drugs.

Antibodies (Ab’s) are also known as an immunoglobulin (Ig) that are large, Y-shaped protein produced by plasma cells which are used by the immune system to detect, identify and neutralize pathogens such as Viruses and bacteria. The antibody recognizes a harmful agent, called an antigen, via the Fab's variable region. Depending on the type of antigen, the binding may inhibit the biological process causing the disease or could activate macrophages to destroy the foreign substance.

Europe's Antibody market is driven by innovative products, increasing rate of adoption to therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies.

The high cost of treatment and side effects associated with antibody treatment are the restraints that are affecting the growth of the market.

This research report has been segmented and sub-segmented into the following categories:

  • By Product Type: Monoclonal Antibodies, Polyclonal Antibodies, Anti-body drug complexes.
  • By Indication: Cancer, Autoimmune diseases, Infectious diseases, cardiovascular diseases, CNS disorders, others.
  • By End User: Hospitals/Clinics, Research institute, Diagnostics laboratories
  • By Application: Medical, Experimental.
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe.

On the Basis of Product Type, Monoclonal antibodies segment accounts for the highest market share in the market.

On the Basis of End User, the Cancer indication type segment is predicted to account highest market share over the forecast period due to broad range applications of monoclonal antibodies for the treatment of various cancers.

Key market participants in the European Antibodies Market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and company, A.G. Scientific, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd and AbbVie Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies     

                                                5.1.1.1 Murine

                                                5.1.1.2 Chimeric

                                                5.1.1.3 Humanized

                                                5.1.1.4 Human 

                                5.1.2 Polyclonal Antibodies         

                                                5.1.2.1 Type I

                                                5.1.2.2 Type II

                                                5.1.2.3 Type III

                                                5.1.2.4 Type IV

                                                5.1.2.5 Type V

                                                5.1.2.6 Type VI

                                                5.1.2.7 Type VII

                                                5.1.2.8 Type VIII

                                5.1.3 Antibody-Drug Complexes

                                                5.1.3.1 Immunogen Technology

                                                5.1.3.2 Seattle Genetics Technology

                                                5.1.3.3 Immunomedics Technology

                5.2 By Indication                              

                                5.2.1 Cancer      

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Europe                         

                                6.1.1 Introduction           

                                6.1.2 U.K             

                                6.1.3 Spain         

                                6.1.4 Germany 

                                6.1.5 Italy           

                                6.1.6 France      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Antibodies Development                         

                                7.5.1 Targeted Therapies             

                7.6 Promising Antibodies in Pipeline                       

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies                            

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Merck KGaA (Germany)                        

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 bioMerieux (France)               

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Qiagen N.V. (Netherlands)                

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  2. Europe Monoclonal Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  3. Europe Polyclonal Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  4. Europe Antibody-Drug complexes Market, By Region, From 2020 to 2025 (USD Million)
  5. Europe Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  6. Europe Cancer Market, By Region, From 2020 to 2025 (USD Million)
  7. Europe Auto immune diseases Market, By Region, From 2020 to 2025 (USD Million)
  8. Europe infectious diseases Market, By Region, From 2020 to 2025 (USD Million)
  9. Europe Cardiovascular diseases Market, By Region, From 2020 to 2025 (USD Million)
  10. Europe CNS disorders Market, By Region, From 2020 to 2025 (USD Million)
  11. Europe Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  12. Europe Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  13. Europe Research institute Market, By Region, From 2020 to 2025 (USD Million)
  14. Europe Diagnostics laboratories Market, By Region, From 2020 to 2025 (USD Million)
  15. Europe Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  16. Europe Medical Market, By Region, From 2020 to 2025 (USD Million)
  17. Europe Experimental Market, By Region, From 2020 to 2025 (USD Million)
  18. U.K. Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  19. U.K. Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  20. U.K. Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  21. U.K. Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  22. Germany Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  23. Germany Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  24. Germany Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  25. Germany Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  26. France Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  27. France Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  28. France Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  29. France Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  30. Italy Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  31. Italy Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  32. Italy Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  33. Italy Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  34. Spain Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  35. Spain Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  36. Spain Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  37. Spain Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  38. Europe Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  39. Europe Murine Market, By Region, From 2020 to 2025 (USD Million)
  40. Europe Chimeric Market, By Region, From 2020 to 2025 (USD Million)
  41. Europe Humanized Market, By Region, From 2020 to 2025 (USD Million)
  42. Europe Human Market, By Region, From 2020 to 2025 (USD Million)
  43. U.K. Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  44. Germany Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  45. France Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  46. Italy Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  47. Spain Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  48. Europe Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  49. Europe Type I Market, By Region, From 2020 to 2025 (USD Million)
  50. Europe Type II Market, By Region, From 2020 to 2025 (USD Million)
  51. Europe Type III Market, By Region, From 2020 to 2025 (USD Million)
  52. Europe Type IV Market, By Region, From 2020 to 2025 (USD Million)
  53. Europe Type V Market, By Region, From 2020 to 2025 (USD Million)
  54. Europe Type VI Market, By Region, From 2020 to 2025 (USD Million)
  55. Europe Type VII Market, By Region, From 2020 to 2025 (USD Million)
  56. Europe Type VIII Market, By Region, From 2020 to 2025 (USD Million)
  57. U.K. Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  58. Germany Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  59. France Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  60. Italy Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  61. Spain Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  62. Europe Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  63. Europe Immunogen Technology Market, By Region, From 2020 to 2025 (USD Million)
  64. Europe Seattle Genetics Technology Market, By Region, From 2020 to 2025 (USD Million)
  65. Europe Immunomedics technology Market, By Region, From 2020 to 2025 (USD Million)
  66. U.K. Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  67. Germany Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  68. France Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  69. Italy Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  70. Spain Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  71. Europe Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  72. Europe Western Blot Market, By Region, From 2020 to 2025 (USD Million)
  73. Europe ELISA Market, By Region, From 2020 to 2025 (USD Million)
  74. Europe Radioimmune Assays Market, By Region, From 2020 to 2025 (USD Million)
  75. Europe immunoflourscence Market, By Region, From 2020 to 2025 (USD Million)
  76. U.K. Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  77. Germany Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  78. France Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  79. Italy Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  80. Spain Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample